COMFORT UCHE: Open Payments
NPI 1043817703 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,267 in 54 payments from 11 companies in 2025. Trend: 2023 $78 · 2024 $299 · 2025 $1,267
Food & beverage: $1,267
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 25 | $583 |
| Gilead Sciences, Inc. | 10 | $238 |
| Eisai Inc. | 4 | $110 |
| Intercept Pharmaceuticals, Inc. | 4 | $94 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $81 |
| Ipsen Biopharmaceuticals, Inc | 2 | $44 |
| ORPHALAN INC | 2 | $44 |
| Amgen Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Novo Nordisk Inc | 1 | $17 |
Products named: REZDIFFRA, Lenvima, OCALIVA, XIFAXAN, IQIRVO, CUVRIOR, UPLIZNA, LIVTENCITY.
Industry payments across TX — which companies pay providers there.
